FILTERED RESULTS
FILTERS
Ads Top
DARK MODE
CHART
    Filters
      Symbols
      Sentiment
      Impact
      Search
      FILTERED RESULTS

        

      Upgrade your plan

      Biogen Acquires Exclusive Rights to Felzartamab in Greater China

      Biogen has finalized an agreement with TJ Biopharma to acquire exclusive worldwide development and commercialization rights to felzartamab, a CD38-directed antibody. This move consolidates all global rights to the drug under Biogen's ownership, enhancing its strategic position in the biopharmaceutical market.

      The agreement is significant for Biogen as it aims to advance felzartamab's potential applications across various immune-mediated conditions in the Greater China Region. This area is recognized as a key global market for biopharmaceuticals, presenting substantial opportunities for growth.

      The partnership builds on the successful development of felzartamab by TJ Biopharma in China, highlighting a productive clinical collaboration between the two companies. Biogen's acquisition is expected to leverage this existing success to further enhance the drug's market presence.

      © 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

      Source: KLEA News

      .

      Terra Founder Do Kwon Sentenced to 15 Years in Prison for Fraud